目的:为了确定单剂量的NSAIDs苯丁酮的作用,费罗昔布,氟尼辛葡甲胺,和酮洛芬对自体蛋白溶液(APS)和富血小板血浆(PRP)中生长因子和细胞因子浓度的影响。
方法:6匹成人大学拥有的马。
方法:对于第一阶段,6匹马随机接受酮洛芬(1,000mg)或氟尼辛葡甲胺(500mg)IV。在施用NSAID之前和之后6小时获得血液并处理APS(Pro-Stride)和PRP(Restigen)。马经历了2周的冲洗期,之后使用交叉设计重复方案.第二阶段,经过至少2周的冲洗期,口服苯丁酮(1g)或氟考昔(57mg)重复研究方案.给药后6小时收集血浆以评估药物浓度,并分析了APS和PRP的药物浓度,血小板,白细胞,以及几种生长因子和细胞因子(PDGF,成纤维细胞生长因子,TGF-β1,IL-1β,IL-10,IL-6,IL-8和肿瘤坏死因子-α)在使用免疫测定法施用NSAID之前和之后6小时。
结果:在任何NSAID给药之前或之后,细胞因子或生长因子的浓度没有显著差异。基于产物和时间,白细胞和血小板的浓度存在显著差异。血浆中的NSAID浓度与APS和PRP中的浓度没有显着差异。
结论:这些结果有助于指导临床医生在APS和PRP的处理中适当使用这些NSAIDs,单剂量给药后不太可能显着改变最终产品。
OBJECTIVE: To determine the effects of a single dose of the NSAIDs phenylbutazone, firocoxib, flunixin meglumine, and ketoprofen on concentrations of growth factors and cytokines in autologous protein solution (APS) and platelet-rich plasma (PRP).
METHODS: 6 adult university-owned horses.
METHODS: For the first phase, 6 horses were randomized to receive ketoprofen (1,000 mg) or flunixin meglumine (500 mg) IV. Blood was obtained and processed for APS (Pro-Stride) and PRP (Restigen) before and 6 hours after administration of NSAIDs. Horses underwent a 2-week washout period, after which the protocol was repeated using a crossover design. For the second phase, following at least a 2-week washout period, the study protocol was repeated with phenylbutazone (1 g) or firocoxib (57 mg) administered orally. Plasma was collected 6 hours after administration for evaluation of drug concentrations, and APS and PRP were analyzed for concentrations of drug, platelets, leukocytes, and several growth factors and cytokines (PDGF, fibroblast growth factor, TGF-β1, IL-1β, IL-10, IL-6, IL-8, and tumor necrosis factor-α) before and 6 hours after administration of NSAIDs using immunoassays.
RESULTS: There were no significant differences in concentrations of cytokines or growth factors before or after administration of any NSAID. There were significant differences in concentrations of leukocytes and platelets based on both product and time. NSAID concentrations in plasma were not significantly different from concentrations in APS and PRP.
CONCLUSIONS: These results help guide clinicians on the appropriate use of these NSAIDs in conjunction with the processing of APS and PRP, which is unlikely to significantly alter the final product after single-dose administration.